Esperion Therapeutics Inc (ESPR) concluded trading on Wednesday at a closing price of $1.63, with 3.62 million shares of worth about $5.89 million changed hands on the day. On March 26, 2025 the price saw a loss of about -2.98%. Currently the company’s common shares owned by public are about 195.85M shares, out of which, 194.37M shares are available for trading.
Stock saw a price change of -2.40% in past 5 days and over the past one month there was a price change of -5.78%. Year-to-date (YTD), ESPR shares are showing a performance of -25.91% which decreased to -28.82% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.47 but also hit the highest price of $3.94 during that period. The average intraday trading volume for Esperion Therapeutics Inc shares is 4.25 million. The stock is currently trading 0.49% above its 20-day simple moving average (SMA20), while that difference is down -9.95% for SMA50 and it goes to -22.93% lower than SMA200.
Esperion Therapeutics Inc (NASDAQ: ESPR) currently have 195.85M outstanding shares and institutions hold larger chunk of about 65.74% of that.
The stock has a current market capitalization of $322.50M and its 3Y-monthly beta is at 0.81. It has posted earnings per share of -$0.27 in the same period. It has Quick Ratio of 0.99. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ESPR, volatility over the week remained 5.74% while standing at 7.29% over the month.
Stock’s fiscal year EPS is expected to rise by 83.04% while it is estimated to decrease by -345.61% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Goldman on December 18, 2024 offering a Neutral rating for the stock and assigned a target price of $4 to it. Coverage by Cantor Fitzgerald stated Esperion Therapeutics Inc (ESPR) stock as an Overweight in their note to investors on December 17, 2024, suggesting a price target of $8 for the stock. Stock get a Neutral rating from JP Morgan on November 20, 2023.
